Rag2−/−mice (n=10) were injected i.v. with PBS alone (A), T cells isolated from naive WT (B) or SD-4 KO (C) mice, and EAE-immunized. Clinical scores (median) were assessed daily, plotted in a scatter chart, and sorted to early- (day 10), mid- (day 20) or late-phases (day 30) (D) with statistical significance of scores (*p<0.01) between mice injected with WT-T cells and KO-T cells. (E) Spinal cords of mice (injected with T cells from WT or KO mice) 20 days after immunization were stained with H&E and examined under a microscope (4 X magnification). (F) IFN-γ- or IL-17-producing cells from spleen of mice injected with PBS, or T cells from WT or KO mice 10 days after immunization were counted by ELISPOT assay and calculated as number per spleen. *p<0.001 between WT- and KO-T cells. Data are representative of 2 independent experiments.